Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial
| Autor: | Mauro Picardo, Wiete Westerhof, Maria Lucia Dell'Anna, P. G. Calzavara, Monica Ottaviani, R. Sala, Arianna Mastrofrancesco, Giovanni Leone, Marina Venturini, Andrea Paro Vidolin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Antioxidant medicine.medical_treatment Placebo-controlled study Vitiligo Skin Pigmentation Dermatology Ascorbic Acid Placebo medicine.disease_cause Ultraviolet therapy Gastroenterology Severity of Illness Index Antioxidants Double-Blind Method Internal medicine Medicine Humans Vitamin D chemistry.chemical_classification biology Thioctic Acid business.industry Middle Aged medicine.disease Combined Modality Therapy Drug Combinations Treatment Outcome chemistry Catalase biology.protein Female Ultraviolet Therapy business Oxidation-Reduction Oxidative stress Polyunsaturated fatty acid |
| Popis: | Vitiligo is an acquired depigmenting disease with uncertain aetiopathogenesis, possibly associated with oxidative stress. Narrowband ultraviolet B phototherapy (NB-UVB) is the most widely used and effective treatment.To evaluate the clinical effectiveness of NB-UVB and the repairing of oxidative stress-induced damage, using oral supplementation with an antioxidant pool (AP).Patients (n = 35) with nonsegmental vitiligo were enrolled in a randomized, double-blind, placebo-controlled multicentre trial. The treatment group received, for 2 months before and for 6 months during the NB-UVB treatment, a balanced AP containing alpha-lipoic acid, vitamins C and E, and polyunsaturated fatty acids. The area and number of lesions, as well as some parameters of the oxidation-reduction (redox) status of the peripheral blood mononuclear cells (PBMCs) were estimated at the beginning, after 2 months, and at the end of the trial.In total, 28 patients completed the study. After 2 months of AP supplementation, the catalase activity and the production of reactive oxygen species (ROS) were 121% and 57% of the basal values (P0.05 and P0.02 vs. placebo, respectively). The AP increased the therapeutic success of NB-UVB, with 47% of the patients obtaining75% repigmentation vs. 18% in the placebo group (P0.05). An increase in catalase activity to 114% (P0.05 vs. placebo) and decrease in ROS level of up to 60% (P0.02 vs. placebo) of the basal value was observed in PBMCs. Finally, the AP intake maintained the membrane lipid ratio (saturated : unsaturated fatty acids 1.8 : 3.1; P0.05), counteracting phototherapy-induced saturation.Oral supplementation with AP containing alpha-lipoic acid before and during NB-UVB significantly improves the clinical effectiveness of NB-UVB, reducing vitiligo-associated oxidative stress. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|